C12N 2750/14132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2750/14132 (Use of virus as therapeutic agent, other than vaccine) appears on 131 US grants and 255 published applications in this corpus.
Search patents in C12N- Granted patents
- 131
- Published applications
- 255
- Assignees
- 131
- Inventors
- 353
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 1 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 3 |
| 2010 | 1 | 2 |
| 2011 | 1 | 4 |
| 2012 | 3 | 4 |
| 2013 | 1 | 7 |
| 2014 | 1 | 8 |
| 2015 | 6 | 7 |
| 2016 | 8 | 24 |
| 2017 | 8 | 16 |
| 2018 | 14 | 16 |
| 2019 | 6 | 19 |
| 2020 | 10 | 43 |
| 2021 | 7 | 12 |
| 2022 | 13 | 14 |
| 2023 | 17 | 10 |
| 2024 | 17 | 18 |
| 2025 | 9 | 20 |
| 2026 | 7 | 22 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs16 Jun 2026US 12,655,427 B2Research Institute At Nationwide Children's Hospital
- Immunomodulating gene therapy26 May 2026US 12,636,302 B2Duke University
- RAAV-based compositions and methods19 May 2026US 12,630,824 B2University of Massachusetts
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4)12 May 2026US 12,624,396 B2Fred Hutchinson Cancer Center
- Process of making membrane lipid coated nanoparticles14 Apr 2026US 12,599,574 B2Coastar Therapeutics Inc.
- Nannochloropsis-producing viruses and methods and compositions for making the same1 Oct 2026US 2026/0297502 A1Insmed Incorporated
- Novel Fragile X Constructs1 Oct 2026US 2026/0297623 A1uniQure biopharma B.V.
- Aav9-mediated gene therapy for treating mucopolysaccharidosis type i24 Sep 2026US 2026/0284155 A1The Trustees of the University of Pennsylvania
- Methods and Compositions for Treating Osteoarthritis10 Sep 2026US 2026/0263499 A1Genascence Corporation
- Parvovirus compositions and related methods for gene therapy10 Sep 2026US 2026/0265310 A1Carbon Biosciences, Inc.
Most cited
By later US patents
- Recombinant adeno-associated vectors for targeted treatment106US 8,927,514 B2City of Hope · 2015
- Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy60US 10,577,630 B2Massachusetts Institute of Technology · 2020
- Recombinant adeno-associated vectors for targeted treatment60US 9,623,120 B2City of Hope · 2017
- Capsid-modified rAAV vectors and methods of use49US 9,775,918 B2University of Florida Research Foundation, Inc. · 2017
- Viral vectors with modified transduction profiles and methods of making and using the same41US 9,409,953 B2The University of North Carolina at Chapel Hill · 2016